VIVUS (VVUS) Sell Off Overdone; Wells Says All Drugs Have Abandonment, Co-Pay Issues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Jefferies Slashes Numbers on Vivus (VVUS) on Slow Qsymia Uptake; Sees Another 45% Downside
November 7, 2012 12:33 PM ESTJefferies slashed its price target on Underperform-rated Vivus (NASDAQ: VVUS) Wednesday from $13 to $6 to reflect the slow Qsymia uptake.
VVUS disclosed that there have been 5,560 Qsymia prescriptions shipped through October 26. This is 30% below the IMS data (7,865 after applying adjustment factors) and SHA (formerly Wolters Kluwer) data... More
Needham & Company Cuts Numbers on VIVUS Inc. (VVUS) on Slower Qsymia Launch, Keeps Buy on Blockbuster Potential
November 6, 2012 3:02 PM ESTNeedham & Company lowered estimates and its price target on Vivus (NASDAQ: VVUS) from $32 to $20 following Q3 results, but kept its Buy rating.
Qsymia was launched in the U.S. in mid-Sept. and were $41,000 during the abbreviated quarter. The company noted 3504 unique patients filled... More
VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay
November 6, 2012 9:25 AM ESTVIVUS (Nasdaq: VVUS) continues to sink following comments on its quarterly conference call Tuesday morning.
The following are a few key pieces from VIVUS conference call:3,504 patients are on Qsymia to date;
Average price for 1-month supply is $160, with 20 percent reimbursement... More
VIVUS (VVUS) Ticks Lower; Wider Q3 Loss Attributed to Qsymia Launch, Expansion (ARNA) (OREX)
November 6, 2012 8:56 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is trading higher in early action following third-quarter results issued earlier.
Though revs were just $41 million, VIVUS noted that, "[g]iven the lack of history in selling Qsymia, VIVUS will recognize revenue on the sell-through method, that is, revenue is recognized as prescriptions... More
VIVUS, Inc. (VVUS) Posts Wider than Expected Q3 Loss of 40c/Share
November 6, 2012 8:16 AM ESTVIVUS, Inc. (Nasdaq: VVUS) reported Q3 EPS of ($0.40), $0.09 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $41 thousand versus the consensus estimate of $310 thousand.
For earnings history and earnings-related data on Vivus, Inc. (VVUS) click here.... More
